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Background and purpose: Organ preservation strategies are increasingly being explored for early rectal
cancer. This requires revision of target volumes according to disease stage, as well as new guidelines
for treatment planning. We conducted an international, multicentre dose planning study to develop
robust planning objectives for modern radiotherapy of a novel mesorectal-only target volume, as imple-
mented in the STAR-TReC trial (NCT02945566).
Materials and methods: The published literature was used to establish relevant dose levels for organ at
risk (OAR) plan optimisation. Ten representative patients with early rectal cancer were identified.
Treatment scans had mesorectal target volumes as well as bowel cavity, bladder and femoral heads out-
lined, and were circulated amongst the three participating institutions. Each institution produced plans
for short course (SCRT, 5  5 Gy) and long course (LCRT, 25  2 Gy) treatment, using volumetric modu-
lated arc therapy on different dose planning systems. Optimisation objectives for OARs were established
by determining dose metric objectives achievable for 90% of plans.
Results: Sixty plans, all fulfilling target coverage criteria, were produced. The planning results and liter-
ature review suggested optimisation objectives for SCRT: V10Gy < 180 cm3, V18Gy < 110 cm3, V23Gy < 85 cm3
for bowel cavity; V21Gy < 15% and V25Gy < 5% for bladder; and V12.5Gy < 11% for femoral heads.
Corresponding objectives for LCRT: V20Gy < 180 cm
3, V30Gy < 130 cm
3, V45Gy < 90 cm
3 for bowel cavity;
V35Gy < 22% and V50Gy < 7% for bladder; and V25Gy < 15% for femoral heads. Constraints were validated
across all three institutions.
Conclusion: We utilized a multicentre planning study approach to develop robust planning objectives for
mesorectal radiotherapy for early rectal cancer.
 2019 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy &
Oncology. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/
4.0/).Introduction
Radiotherapy for rectal cancer has traditionally been used in the
neoadjuvant setting, prior to radical surgery. Standard total
mesorectal excision (TME) surgery can, however, result in signifi-
cant morbidity and mortality. There is consequently an increasing
interest in organ preservation and non-surgical management
strategies. This is currently primarily considered when the stan-dard of care involves pre-operative chemoradiotherapy, generally
in patients with a moderate or high risk of local recurrence, who
have a complete clinical response to treatment.
In early stage rectal cancer with a low local recurrence risk after
radical surgery, patients do not usually receive preoperative radio-
therapy. The benefit of organ preservation approaches compared
with radical surgery are being evaluated in this setting in the inter-
national phase III STAR-TREC trial (ClinicalTrials.gov Identifier:
NCT02945566) [1]. This trial focuses on early stage cancer and
requires a re-evaluation of target volumes and treatment planning
principles. The rationale and development of a novel mesorectum-
only target volume for early rectal cancer has been discussed else-
Table 1
Patient characteristics. All continuous measures represent median
values with interquartile range in brackets. CTV: Clinical target
volume. PTV: Planning target volume. Patients treated in the
prone position did not use a belly board.
Patient characteristics
Gender 4 female/6 male
Treatment position 5 prone/5 supine
Disease stage 1 T1/8 T2/1 T3a
10 N0
T site in rectum 1 high/5 mid/4 low
CTV [cm3] 226 (176–238)
PTV [cm3] 526 (458–568)
Bowel cavity [cm3] 946 (693–1354)
Bowel loops [cm3] 381 (144–492)
Bladder [cm3] 201 (115–304)
Right femoral head [cm3] 169 (129–215)
Left femoral head [cm3] 169 (129–216)
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not yet been described.
In STAR-TREC, we aim to spare the pelvic normal tissues from
unnecessary irradiation and minimise acute toxicity [3] and late
toxicity [4]. This is achieved with the use of intensity modulated
radiotherapy or arc therapy and pre-specified treatment planning
objectives for the relevant organs at risk. As for any other introduc-
tion of radiotherapy regimens and volumes in novel settings, iden-
tification of treatment planning objectives can prove challenging,
as limited data are available. Alternative approaches may be
needed, in the absence of clinical outcome data to drive OAR con-
straints, to reduce dose to normal tissue as far as reasonably
achievable.
The purpose of the current study was to establish organs at risk
(OAR) dose metric optimisation objectives for evaluation of inver-
sely planned IMRT mesorectum-only treatment plans. These would
aim to ensure that a majority of treatment plans are sufficiently
conformal with respect to the OARs. We set out to develop and
subsequently confirm the robustness of the optimisation objec-
tives across multiple dose planning systems and individual
planners.Materials and methods
Literature search
A systematic search was conducted on PubMed, using a combi-
nation of keywords representing variations of ‘‘radiotherapy”,
‘‘gastrointestinal toxicity” and ‘‘dose-response” or ‘‘dose-volume”,
published in English language up to May 2018. See Appendix A
(supplementary materials, online only) for details. We identified
studies reporting correlations between dose metrics and early
and late bowel toxicity with external beam radiotherapy, and per-
formed a narrative review of those. A similar search and review
were conducted for bladder toxicity (‘‘radiotherapy”, ‘‘bladder tox-
icity” and ‘‘dose-response” or ‘‘dose-volume”), deliberately focus-
ing on papers describing outcomes after rectal cancer treatment,
and for femoral head toxicity. Due to the novel target volume con-
sidered here, and variation in normal tissue delineation across the
literature, no attempt was made to identify specific dose metric
cut-offs in previous publications. We divided the identified dose
levels into those relevant for establishment of plan optimisation
objectives and those mainly relevant for plan comparisons in the
current study.Patients
Ten patients with early rectal cancer (T1-3a, N0) were identified
from patient records at Leeds Cancer Centre, UK, and were selected
to include a range of male and female patient anatomy; patients
with high/mid and low tumours; and patients treated in prone
and supine position. See Table 1 for patient characteristics. Local
Leeds Teaching Hospitals Trust (LTHT) Research & Development
approval was obtained for use of patient data.
Patients were scanned for treatment planning using 5 mm CT
slice thickness. Mesorectal-only target volumes (clinical target vol-
ume, CTV) were delineated according to the STAR-TREC contouring
guidelines (Peters et al., submitted). In brief, this volume includes
the mesorectum and pre-sacral lymph nodes at the level of the
tumour, two centimetres below and cranially up to the S2-3 inter-
space level. The lateral lymph nodes and the nodes along the supe-
rior rectal artery are excluded. The planning target volumes (PTV)
were created using 10 mm craniocaudal, posterior and lateral mar-
gins and 15 mm anterior margins. The bowel cavity was outlined
using adapted RTOG guidelines, including the abdominal contentsbut excluding major vasculature, muscles and bones, as well as
other pelvic organs (e.g. bladder, prostate, vagina, uterus), extend-
ing 2 cm above the superior extent of the PTV and inferiorly to
where small bowel or colon is visible. The mesorectum and rectum
were excluded from the volume. Due to the uncertainty surround-
ing optimal bowel definition for pelvic radiotherapy planning, indi-
vidual bowel loops were additionally contoured as a separate
volume, to allow evaluation of dose metrics (but not to be used
for plan optimisation). The whole bladder was delineated including
urine compartment and bladder wall. The right and left femoral
heads were contoured separately, with the caudal extension inferi-
orly to the lesser trochanter. All outlining was done by an experi-
enced clinical oncologist consultant (who wrote central aspects
of the contouring guidelines), with support from a GI radiologist
and feedback from other senior trial members. Table 1 contains
information regarding target and OAR volumes for the patient
cohort.
Treatment planning and evaluation
Three experienced planners from three major academic radio-
therapy centres (St James University Hospital, Leeds, UK; Leiden
University Medical Center, Leiden, Netherlands; Aarhus University
Hospital, Aarhus, Denmark) produced two plans each for each
patient case: (1) Long-course radiotherapy plan of 50 Gy in 25 frac-
tions; (2) Short course radiotherapy plan of 25 Gy in 5 fractions.
Each centre used a different planning system: Eclipse (Varian Med-
ical Systems), Pinnacle (Philips Healthcare), and Monaco (Elekta).
Planners were asked to produce as conformal plans as possible,
while ensuring that they would be deliverable and acceptable in
their local clinical practice with respect to physical plan parame-
ters, treatment time, plan robustness, and general clinical setup.
Each centre reviewed their treatment plan strategy (beam setup,
prioritisation of planning objectives, etc) with a radiation oncolo-
gist experienced in rectal cancer treatment. Target planning objec-
tives followed standard ICRU 83 criteria, focusing on full coverage
of the target volume with the 95% isodose (V95%  100% for CTV,
V95%  99% for PTV), no hotspots (V105%  1% for PTV), and keeping
the median target dose (D50%) within 2% of the prescription dose.
Generally, target volume (PTV) dose homogeneity, coverage and
conformity were prioritised over specific OAR sparing.
Eclipse: Arc therapy treatment plans consisted of a full dual arc
over 358, delivered using a 15 MV beam. Arcs had control points
every 2. Dose calculation was performed with the Varian Acuros
XB algorithm, with 2 mm grid spacing.
Pinnacle: Arc therapy treatment plans consisted of a dual partial
arc over 268, to avoid the bowel cavity and the bladder, delivered
using a 10 MV beam. Arcs had control points every 4. Dose calcu-
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4 mm grid spacing.
Monaco: Arc therapy treatment plans consisted of either a full
dual arc or dual partial arcs (45–180 and 315–110), depending
on patient anatomy, delivered using a 6 MV flattening filter free
(FFF) beam. Arcs had a maximum of 50 control points per arc
and 1 cm minimum segment width. Dose calculation was per-
formed with a Monte Carlo based algorithm, with 3 mm grid spac-
ing and 1% statistical uncertainty.
Dose metrics, as identified in the process described above, were
extracted from dose volume histograms (DVH) in each planning
system and collated across centres. Descriptive statistics (median
and interquartile range, IQR) were summarised for volumes of
interest. Dose metric optimisation objectives achievable for a
majority of patients were originally identified in a single centre
(centre 1) using the following criteria:
(1) For bowel cavity: Objectives chosen to be achievable for at
least 80% of plans.
(2) For bladder and femoral heads: Objectives chosen to be
achievable for at least 90% of plans.
This expert-based approach ideally identifies objectives which
ensure active treatment optimisation for most patients, without
failing more than a small minority after plan optimisation; with
priority given to bowel relative to bladder and femoral heads.
Subsequently, these criteria were tested across dose planning
systems and dose planners, and deemed robust if they fulfilled
the above criteria for any individual centres as well as all being
achievable for 90% of all plans across centres.
Two conformity indices (CIs) were chosen for plan comparison
purposes:
CI1 ¼ V95%;PTV
V95%;patientFig. 1. Between-centre variation in dose planning, for patients with limited and larger var
fractions) and long-course radiotherapy (LCRT, 50 Gy/25 fractions) chosen for illustration
heterogeneity. Treatment planning details for each centre are described in the main text
CTV. Green outline: Planning target volume, PTV. Orange outline: Bowel cavity. Yello
references to colour in this figure legend, the reader is referred to the web version of thCI2 ¼ V50%;patient
Vtotal;PTV
Multiple CIs have been reported in the literature [5]; the ones
used here focus on the conformity of high dose to the PTV and
the spill-over of median dose levels into surrounding normal
tissue.
Results
Literature search: OAR dose levels for LCRT
A substantial number of studies reported results for 3D confor-
mal radiotherapy (3D-CRT), the majority of which has been
reviewed in [6]. Studies in rectal and anal cancer as well as selected
studies in prostate and gynaecological cancer are summarised in
Appendix A (supplementary materials, online only).
Bowel: For rectal cancer patients, preoperatively treated with
3D-CRT, the absolute bowel volume receiving 15 Gy (V15Gy) has
consistently been found to correlate with acute GI toxicity [7–
11]. Studies of rectal [12], anal [13–17], prostate [18–20] and
gynaecological [21–23] cancer patients treated with IMRT or arc
therapy have found correlations between acute GI toxicity and
dose levels from approximately 25–45 Gy, delivered in 25–28 frac-
tions. For late GI toxicity in rectal cancer, the data is very limited.
There is some limited evidence that absolute dose volumes in this
same range (V30Gy–V45Gy) may correlate with late toxicity [6,24–
26]. One high dose level (V45Gy) as well as two medium dose levels
(V20Gy and V30Gy) were chosen for optimisation objectives. Addi-
tionally, V15Gy was chosen for plan comparison purposes.
Bladder: A single study from the neoadjuvant rectal cancer set-
ting was identified [27]. Appelt et al found that relative volume of
the bladder receiving 35 Gy or above (V35Gy) in 25–30 fractions cor-
related with acute urinary toxicity. Data from bladder cancer
patients indicate that long term functional outcome may also beiation in organ at risk (OAR) dose metrics. Short-course radiotherapy (SCRT, 25 Gy/5
, not to indicate that either of the treatment schedules demonstrated more planning
. Red outline: Gross tumour volume, GTV. Dark blue outline: Clinical target volume,
w outline: Bladder. Light blue outline: Femoral heads. (For interpretation of the
is article.)
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quently, V35Gy and V50Gy were chosen as optimisation objectives,
with V15Gy additionally chosen for plan comparison purposes.
Femoral heads: Data on dose-volume relationships for femoral
heads are extremely sparse [28]. Consequently, a pragmatic deci-
sion was made to optimise the volume receiving 50% of the pre-
scription dose (V25Gy) to prevent lateral dose dumping.Literature search: OAR dose levels for SCRT
The vast majority of publications focus on normo-fractioned
(1.8–2.0 Gy) treatment (see previous section), with only two
papers providing any suggestions for optimisation constraints for
SCRT [30,31]. Due to the lack of reliable data, optimisation con-
straints were guided by conversions from 1.8 to 2 Gy per fraction
to 5 Gy per fraction using the linear quadratic model, with
a/b = 10 Gy for acute toxicity and a/b = 3 Gy for late toxicity.
Details of recalculations can be found in Appendix B (supplemen-
tary materials, online only).
Bowel: 30 Gy in 25–28 fractions corresponds to 23 Gy
(a/b = 10 Gy) and 18 Gy (a/b = 3 Gy) in 5 fractions. As 23 GyFig. 2. Boxplots of dose metrics for bowel cavity (a and b) and small bowel loops (c and
optimisation objectives as suggested in Table 2. Circles represent outliers outside 1.5 timadditionally provides a suitable optimisation point close to the pre-
scription dose level, V18Gy and V23Gy were deemed appropriate for
optimisation of SCRT plans. To ensure optimisation of medium/
low dose levels, V10Gy was added to the optimisation objectives,
with V12.5Gy used for plan comparison purposes only (correspond-
ing to 15 Gy in 25 fractions).
Bladder: The same approach as above was used, where 35 Gy
delivered in 25–28 fractions corresponds to 25–26 Gy
(a/b = 10 Gy) and 21 Gy (a/b = 3 Gy) in 5 fractions. Two objectives
representing this range (V21Gy and V25Gy) were chosen; with the
higher dose level controlling the volume of the bladder receiving
prescription dose. V12.5Gy was reported for plan comparison.
Femoral heads: Volume of femoral heads receiving 50% of the
prescription dose (V12.5Gy) was chosen, as for LCRT.Planning results and suggested optimisation objectives
Dose metrics were generally consistent across centres, with the
main variation seen for low dose bowel and bladder metrics,
femoral heads doses, and CI2 (relative proportion between volume
receiving 50% of prescription dose and total volume of PTV). Fig. 1d) for long- and short-course mesorectal-only radiotherapy. Dotted lines indicate
es the interquartile range (IQR).
18 A.L. Appelt et al. / Technical Innovations & Patient Support in Radiation Oncology 11 (2019) 14–21illustrates some of the planning variation seen for two example
patients, mainly related to lateral dose spill to spare anterior struc-
tures. See Figs. 2–4 for visual illustration of the main results.
Based on these results, optimisation objectives were identified
and validated across centres; summarised in Table 2. As described,
these objectives are chosen to be achievable for at least 80%
(bowel) or 90% (bladder, femoral heads) in an individual centre.
On multi-centre validation, all objectives were achievable for 90%
of plans overall. Femoral head objectives are valid for individual
(left/right) femoral heads as well as for the combined volume.
Small bowel loop dose metrics demonstrated large variation
between patients, compared to bowel cavity; many patients had
zero volume of small bowel loops irradiated across most dose
levels. Detailed results for all evaluated dose metrics are presented
in Tables C1 and C2 (Appendix C, supplementary materials, online
only).
Discussion
Our multicentre planning study has identified robust dose plan-
ning objectives appropriate for mesorectal-only radiotherapy.Fig. 3. Boxplots of dose metrics for bladder (a and b) and femoral heads (c and d) for long
objectives as suggested in Table 2. Note that centre 2 did not spare the dose to the femo
added if necessary.These objectives have been chosen to be achievable for the major-
ity of patients planned using modern, intensity modulated treat-
ment techniques. Generally, there is limited clinical evidence
available to guide the choice of dose levels for plan optimisation
in rectal cancer. Given the lack of published data, we used a com-
bination of literature review, expert opinion, and best practice in
academic centres to arrive at pragmatic dose planning objectives.
These now form the basis of the radiotherapy planning recommen-
dations in the STAR-TREC trial.
Short course radiotherapy or chemoradiotherapy may be con-
sidered for patients with early rectal cancer eligible for an organ
preserving approach. In this setting, mesorectal radiotherapy is
attractive, since it is targeted to the primary tumour and the sur-
rounding tissue at risk for involved lymph nodes, minimising tox-
icity and optimising chances for acceptable functional outcome
and quality of life.
To fully employ the benefits of this reduced target volume,
high-quality, conformal radiotherapy is warranted. The literature
available to inform plan optimisation guidelines is sparse, how-
ever, and much of it is from 2D and 3D-CRT treatment era. Data
from 3D-CRT should be used with caution in the IMRT setting, as- and short-course mesorectal-only radiotherapy. Dotted lines indicate optimisation
ral heads as much as possible, the suggested objective for femoral heads was only
Fig. 4. Boxplots of conformity indices (CI1 and CI2, seemain text) for high dose to the PTV (a and b) and spill-over ofmedian dose levels into surrounding normal tissue (c and d)
for long- and short-course mesorectal-only radiotherapy. PTV: Planning target volume.
Table 2
Suggested optimisation objectives for long-course (LCRT) and short-course (SCRT)
mesorectal-only radiotherapy. Femoral head objectives are valid for individual (left/
right) femoral heads as well as for the combined volume.
Optimisation objectives
Organ at risk LCRT (25  2Gy) SCRT (5  5Gy)
Bowel cavity V20Gy < 180 cm3 V10Gy < 180 cm3
V30Gy < 130 cm3 V18Gy < 110 cm3
V45Gy < 90 cm3 V23Gy < 85 cm3
Bladder V35Gy < 22% V21Gy < 15%
V50Gy < 7% V25Gy < 5%
Femoral heads V25Gy < 15% V12.5Gy < 11%
A.L. Appelt et al. / Technical Innovations & Patient Support in Radiation Oncology 11 (2019) 14–21 19close correlation between dose metrics in the 15–50 Gy range for
3D-CRT treatment plans can make it difficult to elucidate any
high- and medium-range dose effect. OAR outlining conventions,
chemotherapy schedules, and supportive care may also have chan-
ged, making it unlikely that specific dose constraints based on non-
contemporary patient series may be directly applicable to modernrectal cancer treatment. Even though absolute dose constraints for
prevention of treatment-related toxicity might not be known,
however, objectives can be established that at least ensure that
plans are optimised and conformal compared to a representative
patient cohort. This paper provides such approach, based on a mul-
ticentre treatment planning study. The methodology presented
here could be relevant for other multicentre trials, and could thus
be of general interest outside the rectal cancer organ preservation
space.
The suggested objectives should ensure a reasonable plan qual-
ity for most patients, although individual patients can likely be
optimised further [32]. We deliberately included a range of patient
cases, to ensure that results are robust for factors known to impact
OAR doses in rectal cancer radiotherapy, such as tumour height,
patient positioning [33] and gender [34]. Thus objectives should
be achievable for most patient groups and across treatment plan-
ning systems; although centres might consider tighter objectives
if consistently achievable for their local patients. Additionally,
the optimisation objectives still leave room for plan variation, as
demonstrated in our data. No optimisation objectives are
20 A.L. Appelt et al. / Technical Innovations & Patient Support in Radiation Oncology 11 (2019) 14–21suggested for low dose levels (<15 Gy for LCRT, <10 Gy for SCRT),
and there might be resulting variation in clinical planning practice,
especially depending on local beam setups (choice of beam angles
for IMRT, partial versus full arcs for arc therapy). The variations in
CI1 and CI2 across centres illustrate this point: Differences might
be explained by disparate prioritisation of e.g. anterior dose spill-
over, high dose conformality, hotspots in OARs, etc, in the plan
optimisation process. Individual clinical teams will likely want to
assess additional plan metrics as part of their plan approval and
prescription process. At this point, we are unable to identify evi-
dence for specific assessment criteria, however.
Other limitations of the current study include the small number
of treatment planners and systems used; ideally all major commer-
cial treatment planning systems should have been included, with
multiple planners and/or institutions per system. The STAR-TREC
trial will allow retrospective plan review across centres and sys-
tems. Comparison of results from arc therapy (used by all centres
in the study) with IMRT would have been interesting, but likely
of limited practical use, as arc therapy is the dominating technique
for intensity modulated delivery in current clinical practice. This
situation could change in the future, as commercial MR-guided
radiotherapy (MRgRT) systems use step-and-shot IMRT for treat-
ment delivery. MRgRT IMRT appears to provide a slightly worse
plan quality compared to conventional linac-based VMAT for rectal
cancer [35], and the current study results may thus not be applica-
ble in this setting. Conversely, MRgRT could potentially allow for
treatment margin reduction: The current study used large, but
appropriate, CTV-to-PTV margins [36], which can very likely be
reduced with daily (MRI) guidance and adaptive strategies. If that
becomes the case, it might be necessary to re-evaluate the sug-
gested planning objectives to ensure optimal plan quality across
future patient populations.
The current study focused on ‘‘classic” pelvic OARs for rectal
cancer radiotherapy; bowel, bladder and femoral heads. In the
organ preservation setting, other normal tissue may emerge as
more relevant for long term functional outcomes and quality of
life. These could include the anal sphincter and pelvic floor muscles
[37–38], pelvic bones [39], and vagina [40] or penile bulb. There is
very little published data optimising rectal cancer radiotherapy in
the organ preservation setting, and basic questions around relevant
patient-experienced toxicity endpoints and OARs still need to be
addressed. High quality clinical data, preferably from prospective
trials, are needed to guide further development.Conclusion
Introduction of radiotherapy regimen and volumes in novel set-
tings can prove challenging, as limited clinical data are available to
guide plan optimisation. We utilized a multicentre planning study
approach to develop robust planning objectives for mesorectal
radiotherapy for early rectal cancer. The suggested objectives
should support the safe implementation of the novel mesorectal
treatment volume in prospective trials, e.g. as currently used in
the STAR-TREC trial.Funding
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